Home » Stocks » AEZS

AEterna Zentaris Inc. (AEZS)

Stock Price: $0.708 USD -0.061 (-7.97%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $0.720 +0.012 (1.74%) Jan 22, 7:59 PM
Market Cap 43.60M
Revenue (ttm) 532,000
Net Income (ttm) -6.04M
Shares Out 17.49M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $0.708
Previous Close $0.769
Change ($) -0.061
Change (%) -7.97%
Day's Open 0.736
Day's Range 0.690 - 0.756
Day's Volume 11,539,019
52-Week Range 0.299 - 1.360

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET –

GlobeNewsWire - 2 weeks ago

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing thera...

GlobeNewsWire - 1 month ago

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmace...

GlobeNewsWire - 2 months ago

- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million   - Novo Nordisk committing to fund €9 million of the budgeted AEZS-1...

GlobeNewsWire - 2 months ago

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021

GlobeNewsWire - 4 months ago

– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth

GlobeNewsWire - 4 months ago

- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT -

GlobeNewsWire - 4 months ago

- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults -

GlobeNewsWire - 5 months ago

 – Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency

GlobeNewsWire - 5 months ago

CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc . (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing t...

GlobeNewsWire - 5 months ago

CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing ...

GlobeNewsWire - 5 months ago

CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and d...

GlobeNewsWire - 5 months ago

CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...

GlobeNewsWire - 5 months ago

CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercia...

GlobeNewsWire - 6 months ago

CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...

GlobeNewsWire - 6 months ago

CHARLESTON, S.C., July 01, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...

GlobeNewsWire - 6 months ago

CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...

GlobeNewsWire - 7 months ago

CHARLESTON, S.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing ...

GlobeNewsWire - 7 months ago

CHARLESTON, S.C., June 04, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing ...

GlobeNewsWire - 8 months ago

CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and de...

GlobeNewsWire - 9 months ago

CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercia...

GlobeNewsWire - 9 months ago

– Modifications recommended for some key elements of planned safety and efficacy Study P02 –

GlobeNewsWire - 9 months ago

– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic –

GlobeNewsWire - 10 months ago

CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and ...

GlobeNewsWire - 11 months ago

CHARLESTON, S.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...

GlobeNewsWire - 11 months ago

CHARLESTON, S.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...

GlobeNewsWire - 11 months ago

Presentation on Monday, February 17th at 11:30 a.m. ET Presentation on Monday, February 17th at 11:30 a.m. ET

GlobeNewsWire - 11 months ago

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic –

GlobeNewsWire - 11 months ago

CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commerci...

GlobeNewsWire - 1 year ago

CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market L...

Zacks Investment Research - 1 year ago

Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 year ago

CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer...

GlobeNewsWire - 1 year ago

CHARLESTON, S.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical t...

GlobeNewsWire - 1 year ago

CHARLESTON, S.C., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a specialty biopharmaceutical company engaged in commercializing ...

Seeking Alpha - 1 year ago

Aeterna Zentaris has had a rough go over since April which forced me to jump ship and sell the remaining shares of AEZS. Now, I am looking to return.

GlobeNewsWire - 1 year ago

CHARLESTON, S.C., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that Jonathan Pollack has resigned as a director of the Company for perso...

Zacks Investment Research - 1 year ago

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 107.14% and -3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Aeterna Zentaris (AEZS) needs investors to pay close attention to the stock based on moves in the options market lately.

Zacks Investment Research - 1 year ago

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the s...

Zacks Investment Research - 1 year ago

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

Seeking Alpha - 1 year ago

AEterna Zentaris recently filed their Q4/2018 earnings report revealing $200K in Macrilen royalties for Q4 and pulling in $26.9M in revenue for 2018.

About AEZS

Aeterna Zentaris, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macri... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 1996
CEO
Klaus Paulini
Stock Exchange
NASDAQ
Ticker Symbol
AEZS
Full Company Profile

Financial Performance

Financial Statements